Addressing Dosing Frequency in Diabetes: A Simple Approach to Improving Adherence to Therapy and Clinical Outcomes

Abstract

Get full access to this article

View all access options for this article.

References

1. Nichols-English G , Poirier S. Optimizing adherence to pharmaceutical care plans. J Am Pharm Assoc. 2000;40:475-485.

2. Stamler J , Stamler R , Neaton J. Blood pressure, systolic and diastolic, and cardiovascular risks. Arch Intern Med. 1993;153:598-615.

3. Bittar N. Maintaining long-term control of blood pressure: the role of improved compliance. Clin Cardiol. 1995;18(6 suppl 3):111-112-111-116.

4. Cohen JS . Adverse drug effects, compliance, and initial doses of antihypertensive drugs recommended by the Joint National Committee vs the Physicians' Desk Reference. Arch Intern Med. 2001;161:880-885.

5. Farmer KC . Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther. 1999;21:1074-1090. Discussion1073.

6. Shobhana R , Begum R , Vijay V , et al. Patients' adherence to diabetes treatment. J Assoc Physicians India. 1999;47:1173-1175.

7. Zambanini A , Newson R , Maisey M , et al. Injection related anxiety in insulin-treated diabetes. Diabetes Res Clin Pract. 1999;46:239-246.

8. Wallace T , Matthews D. Poor glycaemic control in type 2 diabetes: a consirac ofdisese, conspiracy of disease, suboptimal therapy and attitude. Q J Med. 2000;93:369-374.

9. Greenberg R. Overview of patient compliance with medication ment of diabetes. Diadosing: a literature review. Clin Ther. 1984;6:592-599.

10.

10. Sackett DL , Haynes RB Gibson ES et al PaRB, G ib nc t a. tent compliance with as prescribed? A novel antihypertensive regimens. Patient Counsel Health Educ. 1978;1:18-21.

11.

11. Influence of intensive diabetes treatment on body weight on body weight and composition of adults with type 1 diabetes in the Diabetes Control and Complications Trial. Diabetes Care. 2001, 24:1711-1721.

12.

12. United Kingdom Prospective Diabetes Study 24 . A 6-year, randomized, controlled trial comparing sulphonylurea, insulin, and metformin therapy in formin therapy in patients with newly diagnoe type 2 dats nosed type 2 diabetes that could not be controlled with diet therapy. Ann Intern Med. 1998;128:165-175.

13.

13. Cryer PE . Hypoglycaemia is the limithing factor in the management of diabetes. Dianetes Metad Res Rev. 1999; 15:42-46.

14.

14. Cramer J , Mattson R , Prevey M , et al. How often is medication taken assessment technique. JAMA. 1989;261:3273-3277.

15.

15. Andrejak M , Genes N , Vaur L , et al. Electronic pill-boxes in the evaluation of antihypertensive treatment compliance: comparison of once daily versus twice daily regimen. Am J Hypertens. 2000;13:184-190.

16.

16. Funnell MM , Andercomparing sulphonyson RM. The problem urea, insulin, and met with compliance in diabetes. JAMA. 2000; 284:1709-1709.

17.

17. Larme A , Pugh J. Attitudes of primary care providers towards diabetes. Barriers to guideline implementation. Diabetes Care. 1998;21:1391-1396.

18.

18. Donnan PT , Mac-Donald TM . Morris AD . Adtherence to prescribed oral hypoglycaemic medication in a population of patients with type 2 diabetes: a retrospaective cohort study. Diabetic Med. 2002; 19:279-284.

19.

19. Johnson SB . Methodological issues in diabetes research. Measuring adherence. Diabetes Care. 1992;15:1658-1667.

20.

20. Glasgow RE , McCaul KD , Schafer LC . Self-care behaviors and glycemic control in type I diabetes. J Chronic Dis. 1987;40:399-412.

21.

21. Williams L , Lowenthal D. Drug therapy in the elderly. South Med J. 1992;85:127-131.

22.

22. Salzman C , Kupfer D , Frank E. Medication compliance in the elderly. J Clin Psychiatry. 1995;56(suppl 1): 18-23.

23.

23. Grimes D , Hindle E , Dyer T. Respiratory infection and coronary heart disease: progression of a paradigm. Q J Med. 2000;93:375-383.

24.

24. Morley JE , Perry HM 111 . The management of diabetes mellitus in older individuals. Drugs. 1991;41:548-565.

25.

25. Dahl-Jorgensen K. Modern insulin therapy in children and adolescents. Acta Paediatr. 1999;427(suppl):25-30.

26.

26. Morris A , Boyle D , McMahon A , et al. Adherence to insulin treatment, glycaemic control, and ketoacidosis in insulin-dependent diabetes mellitus. Lancet. 1997;350:1505-1510.

27.

27. Rydall AC , Rodin GM , Olmsted MP , et al. Disordered eating behavior and microvascular complications in young women with insulin-dependent diabetes mellitus. N Engl J Med. 1997;336:1849-1854.

28.

28. Kramer W. New approaches to the treatment of diabetes. Exp Clin Endocrinol Diabetes. 1999; 107(suppl 2):S52-S61.

29.

29. Diabetes Control and Complications Trial Research Group . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulindependent diabetes mellitus. N EngI J Med. 1993;329:977-986.

30.

30. UK Prospective Diabetes Study Group . Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.

31.

31. Rosilio M , Cotton JB , Wieliczko MC , et al. Factors associated with glycemic control. A cross-sectional nationwide study in 2,579 French children with type 1 diabetes. The French Pediatric Diabetes Group. Diabetes Care. 1998;21:1146-1153.

32.

32. American Diabetes Association . Position statement. Standards of medical care for patients with diabetes mellitus. Diabetes Care. 2001; 24(suppl 1):S33-S43.

33.

33. Nichols GA , Hillier TA , Javor K , Brown JB . Predictors of glycemic control in insulin-using adults with type 2 diabetes. Diabetes Care. 2000;23:273-277.

34.

34. Peyrot M , McMurry JF Jr , Kruger DF . A biopsychosocial model of glycemic control in diabetes: stress, coping and regimen adherence. J Health Soc Behav. 1999;40:141-158.

35.

35. Navarro R. The issue of noncompliance. Med Interface. 1996;9:70-72.

36.

36. McNabb W.

Adherence in diabetes: can we define it and can we measure it?

Diabetes Care. 1997;20:215-218.

37.

37. Glasgow RE , Toobert DJ . Social environment and regimen adherence among type 11 diabetic patients. Diabetes Care. 1988;11:377-386.

38.

38. Garay-Sevilla ME , Nava LE , Malacara JM , et al. Adherence to treatment and social support in patients with non-insulin dependent diabetes mellitus. J Diabetes Complications. 1995;9:81-86.

39.

39. Diabetes mellitus. World Health Organization Web site. November 1999. Available at: http://www.who.inVinf-fs/en/factl38.htm I. Accessed May 23, 2001.

40.

40. Lee W , Zinman B. From insulin to insulin analogs: progress in the treatment of type 1 diabetes. Diabetes Rev. 1998;6:73-88.

41.

41. Groop LC . Sulfonylureas in NIDDM. Diabetes Care. 1992;15:737-754.

42.

42. Paes A , Bakker A , Soe-Agnie C. Impact of dosage frequency on patient compliance. Diabetes Care. 1997;20:1512-1517.

43.

43. Lepore M , Pampanelli S , Fanelli C , et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes. 2000;49:2142-2148.

44.

44. Heinemann L , Sinha K , Weyer C , et al. Timeaction profile of the soluble, fatty acid acylated long-acting insulin analogue NN304. Diabetic Med. 1999;16:332-338.

45.

45. Ratner RE , Hirsch IB , Neifing JL , et al. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. Diabetes Care. 2000;23:639-643.

46.

46. Rosenstock J , Park G , Zimmerman J. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. US Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group. Diabetes Care. 2000;23:1137-1142.

47.

47. Pieber T , Eugene Jolchine 1 , Derobert E. Efficacy and safety of HOE901 versus NPH insulin in patients with type 1 diabetes. Diabetes Care. 2000;23:157-162.

48.

48. Raskin P Klaff L , Bergenstal R , et al. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. Diabetes Care. 2000;23:1666-1671.

49.

49. Yki-Jarvinen H , Dressler A , Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care. 2000;23:1130-1136.

50.

50. Rosenstock J , Schwartz SL , Clark CMJ , et al. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care. 2001;24:631-636.

51.

51. Hermansen K , Madsbad S , Perrild H , et al. Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy. Diabetes Care. 2001;24:296-301.

52.

52. Sclar DA , Robison LM , Skaer TL , et al. Sulfonylurea pharmacotherapy regimen adherence in a Medicaid population: influence of age, gender, and race. Diabetes Educ. 1999;25:531-538.

53.

53. Porte F , Garber A , Howlett H , et al. Managing the total glycaemic burden in type 2 diabetes with metforminglibenclamide combination therapy [abstract]. Diabetologia. 2001; 44(suppl 1):A234-A234. Abstract900.

54.

54. Muller G , Hartz D , Punter J , et al. Differential interaction of glimepiride and glibenclamide with the beta cell sulphonylurea receptor. 1. Binding characteristics. Biochem Biophys Acta. 1994; 1191:267-277.

55.

55. Rosenstock J , Samols E , Muchmore D , et al. Glimepiride, a new once-daily sulfonylurea. A double-blind, placebo-controlled study of NIDDM patients. Diabetes Care. 1996;19:1194-1199.

56.

56. Guillausseau PJ , Greb W. 24-hour glycemic profile in type 2 diabetic patients treated with gliclazide modified release once daily. Diabetes Metab. 2001; 27:133-137.

57.

57. Simonson DC , Kourides IA , Feinglos M , et al. Efficacy, safety, and dosresponse characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. The Glipizide Gastrointestinal Therapeutic System Study Group. Diabetes Care. 1997;20:597-606.